Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.
Infinity’s most advanced drug candidate, IPI-504, is a proprietary, targeted cancer therapy that preferentially induces the death of cancer cells through inhibition of the heat shock protein 90 complex (Hsp90). In preclinical animal studies of a wide variety of hematological malignancies and solid tumors, IPI-504 has demonstrated utility as both a single agent and in combination with other therapies. Infinity owns all rights to IPI-504 and commenced Phase I clinical trials in July 2005.
Infinity’s second most advanced drug candidate, IPI-609, is another proprietary small molecule that operates through inhibition of the Hedgehog cell signaling pathway. IPI-609 has demonstrated efficacy as a single agent in preclinical animal models of aggressive pancreatic and prostate cancer. Infinity owns all rights to IPI-609 and expects to file an IND in late 2006.
Since inception in late 2001, Infinity has:
Entered clinical trials with a proprietary drug candidate
Discovered and developed a pipeline of innovative preclinical drug candidates
Assembled a management and advisory team of acknowledged industry leaders
Built a fully integrated cancer drug discovery capability
Raised over $130 million from corporate partnerships and premier venture capitalists
Established alliances with several leading pharmaceutical companies for access to Infinity’s small molecule drug technologies.